Sugi Predict

Sugi Predict / Compounds / SCHEMBL4091466

SCHEMBL4091466

SCHEMBL4091466

CCN(c1ccccc1)S(=O)(=O)c1cccc(NC(=O)NC(c2ccc(C(=O)NCCC(=O)O)cc2)c2ccc(C3CCCCC3)cc2)c1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 7/20 0.46
▸ SMN1; SMN2 Q16637 3/20 0.40
▸ KDM4E B2RXH2 2/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ HTT P42858 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ EPHX2 P34913 1/20 0.39
▸ MAPT P10636 4/20 0.39
▸ LMNA P02545 2/20 0.39
▸ TP53 P04637 1/20 0.39
▸ GIPR P48546 3/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ KMT2A Q03164 1/20 0.38
▸ ALDH1A1 P00352 1/20 0.37
▸ MAPK1 P28482 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4092719 0.91 SMN1; SMN2 (0.48) GCGRSMN1; SMN2HTTEPHX2MAPT
SCHEMBL4087821 0.87 GCGR (0.48) GCGROPRM1OPRK1CYP2D6EPHX2
SCHEMBL9071409 0.87 GCGR (0.54) GCGROPRM1OPRK1GIPR
SCHEMBL4091464 0.84 GCGR (0.43) GCGRSMN1; SMN2KDM4EOPRM1OPRK1
SCHEMBL2650880 0.84 GCGR (0.67) GCGROPRM1OPRK1GIPR
SCHEMBL4092716 0.83 CASP3 (0.44) GCGRSMN1; SMN2KDM4EOPRM1OPRK1
SCHEMBL2658771 0.83 GCGR (0.53) GCGRSMN1; SMN2OPRM1OPRK1CYP2D6
SCHEMBL2653146 0.83 GCGR (0.50) GCGRSMN1; SMN2CYP2D6EPHX2MAPT
SCHEMBL2651718 0.83 GCGR (0.50) GCGRSMN1; SMN2HTTCYP2D6EPHX2
SCHEMBL2652649 0.81 GCGR (0.50) GCGRSMN1; SMN2CYP2D6EPHX2GIPR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-20030220350-A1 Glucagon antagonists/inverse agonists PFIZER INC 2003-11-27 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885SMN1; SMN2 3528/4885KDM4E 3664/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885SMN1; SMN2 3528/4885KDM4E 3664/4885
US-20030220350-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885SMN1; SMN2 3528/4885KDM4E 3664/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.